CALGARY, Alberta, March 28, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX)
announced today the publication of two new articles on the effect of apabetalone, a novel small molecule BET (bromodomain and
extra-terminal) inhibitor, in patients with cardiovascular disease and chronic kidney disease.
Kidney & Blood Press Research published: ‘Apabetalone Mediated Epigenetic Modulation is Associated with Favorable Kidney
Function and Alkaline Phosphatase Profile in Patients with Chronic Kidney Disease.’ The association between serum alkaline
phosphatase (ALP) with adverse cardiovascular outcomes, in Chronic Kidney Disease (CKD) patients has previously been reported and
may be a result of increased vascular calcification and inflammation. The publication reports, for the first time, the effects of
pharmacologic epigenetic modulation on levels of ALP and kidney function via apabetalone in CKD patients.
The full report can be accessed here:
https://www.karger.com/Article/FullText/488257
The Company also announced a second publication in Kidney International Reports, titled: ‘Benefit of Apabetalone on Plasma
Proteins in Renal Disease.’ CKD is associated with a progressive loss of renal function and a high risk
of cardiovascular disease. The findings in the article demonstrate plasma proteome dysregulation in patients with
impaired kidney function and the beneficial impact of apabetalone on proteins and pathways linked to chronic kidney disease and its
cardiovascular complications.
The full report can be accessed here: https://www.sciencedirect.com/science/article/pii/S2468024917304576
High-Risk MACE Patients
There is a direct link between heart disease, diabetes and chronic kidney disease. Adults with diabetes are 2-4
times more likely to die from cardiovascular disease than those without diabetes. High blood pressure and diabetes are the main
causes of chronic kidney disease. 50% of people with chronic kidney disease also have diabetes and cardiovascular disease.
Tragically, these patients remain at high-risk for having a Major Adverse Cardiac Event (MACE), which essentially means: heart
attack, stroke or cardio-related death. This is happening at an alarming rate despite these patients taking current
therapies.
About Apabetalone
Resverlogix has the world lead in a new class of drugs with apabetalone, which will potentially be able to treat
a multitude of diseases due to its unique epigenetic mechanism. What differentiates apabetalone from other drugs is that it has a
positive effect on multiple biological processes that cause disease - leading a new paradigm shift in the treatment of diseases.
Rather than targeting each of these disease states individually with a multitude of drugs, apabetalone affects key factors that
underlie multiple disease states.
About Resverlogix
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET
(bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing
genes. Apabetalone is the first and only chronic BET inhibitor selective for the second bromodomain (BD2) within the BET proteins.
This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits
for patients with high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, end-stage renal disease
treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while
maintaining a well described safety profile. Apabetalone is currently being studied in a Phase 3 trial, BETonMACE, in high-risk CVD
patients with type 2 DM and low high-density lipoprotein (HDL), and is expected to be initiated in a Phase 2a kidney dialysis trial
designed to evaluate biomarker changes and safety parameters in up to 30 patients with end-stage renal disease treated with
hemodialysis.
Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).
Follow us on Twitter: @Resverlogix_RVX
For further information please contact:
Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252
Website: www.resverlogix.com
This news release may contain certain forward-looking information as defined under applicable Canadian
securities legislation, that are not based on historical fact, including without limitation statements containing the words
"believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar
expressions. In particular, this news release includes forward looking information relating to the potential role of apabetalone in
the treatment of CVD, DM, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease,
Fabry disease, peripheral artery disease and other orphan diseases. Our actual results, events or developments could be materially
different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or
expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk
factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by
reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are
expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no
obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.
